• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮质厚度变化比高水平的淀粉样蛋白至少提前七年出现。

Cortical thickness changes precede high levels of amyloid by at least seven years.

作者信息

Roe James M, Jagust William J, Landau Susan M, Harrison Theresa M, Grydeland Håkon, Slivka Maksim, Alatorre-Warren José-Luis, Garrido Pablo F, Sørensen Øystein, Grødem Edvard O S, Ward Tyler J, Leonardsen Esten H, Fladby Tormod, Bjørnerud Atle, Walhovd Kristine B, Fjell Anders M, Vidal-Piñeiro Didac, Wang Yunpeng

机构信息

Center for Lifespan Changes in Brain and Cognition (LCBC), Department of Psychology, University of Oslo, Oslo, Norway.

Computational Radiology and Artificial Intelligence, Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.

出版信息

bioRxiv. 2025 Aug 20:2025.08.14.670398. doi: 10.1101/2025.08.14.670398.

DOI:10.1101/2025.08.14.670398
PMID:40894768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393315/
Abstract

Alzheimer's disease (AD) is now defined based on its underlying brain pathology, with the presence of amyloid (Aβ) plaques at high enough levels sufficient to warrant a diagnosis in the absence of cognitive symptoms. High levels of PET-detectable Aβ are widely thought to be the first imaging marker, with structural brain changes detectable on MRI scans thought to occur later. We combined 4570 longitudinal MRIs and 1684 Aβ PET scans from three cognitively healthy cohorts to test the difference in cortical thickness and its change between those that subsequently converted to be Aβ-positive or stayed Aβ-negative, using MRIs acquired exclusively in the years before conversion. We found those that subsequently developed elevated Aβ levels show both thicker cortex and less cortical thinning, even when the last MRI used to estimate their thickness trajectories was acquired at least seven years before conversion. Many effects remained when accounting for quantitative Aβ levels, suggesting some cortical thickness effects may be partly independent of Aβ. Differences in cortical thickness and its change between converters and Aβ-negative individuals showed moderate alignment with patterns of Aβ deposition, and the timing of thickness changes tracked the temporal progression of Aβ accumulation. Thus, if amyloid is AD, we show that high levels of PET-detectable amyloid are not the first imaging marker of AD, as cortical thickness changes can be traced years before pathological amyloid. This has implications for understanding the sequence of events leading up to the earliest stages of AD.

摘要

阿尔茨海默病(AD)现在是根据其潜在的脑病理学来定义的,即淀粉样蛋白(Aβ)斑块的存在水平足够高,在没有认知症状的情况下足以做出诊断。人们普遍认为,PET可检测到的高水平Aβ是首个成像标志物,而MRI扫描中可检测到的脑结构变化则被认为发生在较晚阶段。我们结合了来自三个认知健康队列的4570份纵向MRI和1684份Aβ PET扫描,以测试随后转变为Aβ阳性或保持Aβ阴性的个体之间皮质厚度及其变化的差异,使用的是在转变前几年专门获取的MRI。我们发现,那些随后Aβ水平升高的个体不仅皮质更厚,而且皮质变薄程度更小,即使在用于估计其厚度轨迹的最后一次MRI扫描是在转变前至少七年获取的情况下也是如此。在考虑定量Aβ水平时,许多效应仍然存在,这表明一些皮质厚度效应可能部分独立于Aβ。转变者和Aβ阴性个体之间皮质厚度及其变化的差异与Aβ沉积模式有适度的一致性,厚度变化的时间跟踪了Aβ积累的时间进程。因此,如果淀粉样蛋白就是AD,我们表明PET可检测到的高水平淀粉样蛋白不是AD的首个成像标志物,因为皮质厚度变化可以在病理性淀粉样蛋白出现前数年就被追踪到。这对于理解导致AD最早阶段的事件顺序具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/a58aad6012c1/nihpp-2025.08.14.670398v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/e36dc71a3d1c/nihpp-2025.08.14.670398v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/858a6dfce538/nihpp-2025.08.14.670398v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/36a2bafb4c62/nihpp-2025.08.14.670398v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/8809bf794de6/nihpp-2025.08.14.670398v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/a58aad6012c1/nihpp-2025.08.14.670398v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/e36dc71a3d1c/nihpp-2025.08.14.670398v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/858a6dfce538/nihpp-2025.08.14.670398v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/36a2bafb4c62/nihpp-2025.08.14.670398v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/8809bf794de6/nihpp-2025.08.14.670398v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaf8/12393315/a58aad6012c1/nihpp-2025.08.14.670398v1-f0005.jpg

相似文献

1
Cortical thickness changes precede high levels of amyloid by at least seven years.皮质厚度变化比高水平的淀粉样蛋白至少提前七年出现。
bioRxiv. 2025 Aug 20:2025.08.14.670398. doi: 10.1101/2025.08.14.670398.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Distinct and joint effects of low and high levels of Aβ and tau deposition on cortical thickness.低水平和高水平 Aβ 和 tau 沉积对皮质厚度的独特和共同影响。
Neuroimage Clin. 2023;38:103409. doi: 10.1016/j.nicl.2023.103409. Epub 2023 Apr 19.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
6
A Novel Design of a Portable Birdcage via Meander Line Antenna (MLA) to Lower Beta Amyloid (Aβ) in Alzheimer's Disease.一种通过曲折线天线(MLA)设计的便携式鸟笼,用于降低阿尔茨海默病中的β淀粉样蛋白(Aβ)。
IEEE J Transl Eng Health Med. 2025 Apr 10;13:158-173. doi: 10.1109/JTEHM.2025.3559693. eCollection 2025.
7
Recent advances in the detection and management of motor dysfunction in Alzheimer's disease.阿尔茨海默病运动功能障碍检测与管理的最新进展
Psychiatriki. 2025 May 14. doi: 10.22365/jpsych.2025.012.
8
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
9
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.用于诊断神经母细胞瘤的123I-间碘苄胍闪烁扫描术和18F-氟代脱氧葡萄糖正电子发射断层显像
Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263. doi: 10.1002/14651858.CD009263.pub2.
10
Longitudinal head-to-head comparison of C-PiB and F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.在一项针对显性遗传性阿尔茨海默病的抗淀粉样蛋白β单克隆抗体的 2/3 期临床试验中,进行 C-PiB 和 F-氟比他滨 PET 的纵向对头比较。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2669-2682. doi: 10.1007/s00259-023-06209-0. Epub 2023 Apr 5.

本文引用的文献

1
Brain change trajectories in healthy adults correlate with Alzheimer's related genetic variation and memory decline across life.健康成年人的大脑变化轨迹与阿尔茨海默病相关基因变异以及一生中的记忆力衰退相关。
Nat Commun. 2024 Dec 17;15(1):10651. doi: 10.1038/s41467-024-53548-z.
2
Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.抗淀粉样蛋白β免疫疗法治疗阿尔茨海默病后脑容量变化:与清除淀粉样蛋白相关的假性萎缩。
Lancet Neurol. 2024 Oct;23(10):1025-1034. doi: 10.1016/S1474-4422(24)00335-1.
3
Revised criteria for the diagnosis and staging of Alzheimer's disease.
阿尔茨海默病诊断与分期的修订标准。
Nat Med. 2024 Aug;30(8):2121-2124. doi: 10.1038/s41591-024-02988-7.
4
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准:阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
5
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.描述阿尔茨海默病中淀粉样蛋白时间线上的脑 tau 与认知衰退。
Brain. 2024 Jun 3;147(6):2144-2157. doi: 10.1093/brain/awae116.
6
Biomarker Changes during 20 Years Preceding Alzheimer's Disease.阿尔茨海默病发病前 20 年的生物标志物变化。
N Engl J Med. 2024 Feb 22;390(8):712-722. doi: 10.1056/NEJMoa2310168.
7
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box.神经退行性疾病进展的数据驱动建模:跳出黑箱思维
Nat Rev Neurosci. 2024 Feb;25(2):111-130. doi: 10.1038/s41583-023-00779-6. Epub 2024 Jan 8.
8
The complex pathway between amyloid β and cognition: implications for therapy.淀粉样蛋白β与认知之间的复杂关系:对治疗的启示。
Lancet Neurol. 2023 Sep;22(9):847-857. doi: 10.1016/S1474-4422(23)00128-X. Epub 2023 Jul 13.
9
Distinct and joint effects of low and high levels of Aβ and tau deposition on cortical thickness.低水平和高水平 Aβ 和 tau 沉积对皮质厚度的独特和共同影响。
Neuroimage Clin. 2023;38:103409. doi: 10.1016/j.nicl.2023.103409. Epub 2023 Apr 19.
10
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.淀粉样蛋白和 tau 正电子发射断层扫描(PET)阳性、认知正常的个体未来认知能力下降的风险较高。
Nat Med. 2022 Nov;28(11):2381-2387. doi: 10.1038/s41591-022-02049-x. Epub 2022 Nov 10.